Theravance Biopharma (TBPH) Expected to Announce Quarterly Sales of $5.74 Million

Wall Street brokerages forecast that Theravance Biopharma (NASDAQ:TBPH) will post $5.74 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Theravance Biopharma’s earnings, with the highest sales estimate coming in at $9.12 million and the lowest estimate coming in at $3.50 million. Theravance Biopharma reported sales of $3.09 million in the same quarter last year, which indicates a positive year-over-year growth rate of 85.8%. The business is expected to announce its next quarterly earnings results on Tuesday, May 8th.

On average, analysts expect that Theravance Biopharma will report full-year sales of $50.26 million for the current financial year, with estimates ranging from $40.00 million to $67.90 million. For the next financial year, analysts anticipate that the business will report sales of $90.20 million per share, with estimates ranging from $64.91 million to $105.70 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Theravance Biopharma.

How to Become a New Pot Stock Millionaire

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($1.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.49). The business had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $3.71 million. Theravance Biopharma had a negative return on equity of 136.86% and a negative net margin of 1,855.42%.



TBPH has been the topic of a number of research reports. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub downgraded shares of Theravance Biopharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 20th. Leerink Swann raised their price objective on shares of Theravance Biopharma from $45.00 to $48.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Piper Jaffray reaffirmed an “overweight” rating and set a $45.00 price target on shares of Theravance Biopharma in a report on Thursday, March 29th. Finally, Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Tuesday, February 27th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $42.43.

Large investors have recently modified their holdings of the business. Woodford Investment Management Ltd lifted its holdings in Theravance Biopharma by 0.4% during the fourth quarter. Woodford Investment Management Ltd now owns 10,747,108 shares of the biopharmaceutical company’s stock valued at $227,270,000 after purchasing an additional 41,000 shares in the last quarter. Virtus Fund Advisers LLC purchased a new position in Theravance Biopharma during the fourth quarter valued at approximately $974,000. Teacher Retirement System of Texas purchased a new position in Theravance Biopharma during the fourth quarter valued at approximately $416,000. Schwab Charles Investment Management Inc. lifted its holdings in Theravance Biopharma by 4.2% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 199,677 shares of the biopharmaceutical company’s stock valued at $5,569,000 after purchasing an additional 8,119 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in Theravance Biopharma during the fourth quarter valued at approximately $313,000. 85.98% of the stock is currently owned by institutional investors and hedge funds.

Shares of TBPH traded up $0.49 on Wednesday, reaching $22.55. The company’s stock had a trading volume of 256,656 shares, compared to its average volume of 242,950. The company has a current ratio of 6.05, a quick ratio of 5.79 and a debt-to-equity ratio of 1.94. The company has a market cap of $1,208.83, a price-to-earnings ratio of -4.14 and a beta of 1.81. Theravance Biopharma has a 12-month low of $21.27 and a 12-month high of $43.44.

COPYRIGHT VIOLATION NOTICE: “Theravance Biopharma (TBPH) Expected to Announce Quarterly Sales of $5.74 Million” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2018/04/23/theravance-biopharma-tbph-expected-to-announce-quarterly-sales-of-5-74-million.html.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply